{"prompt": "Make reference to the context given to assess the scenario. If you do not know the answer. just say that \"I don't know\", don't try to make up an answer.\nYou are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step\n\nANALYSE the given patient profile based on given query based on one of the following criteria:\n- Freshly treated patient or patient under maintenance\n- Prior response to Infliximab\n- Prior failure to Anti-TNF agents\n- Prior failure to Vedolizumab\n- Age\n- Pregnancy\n- Extraintestinale manifestations\n- Pouchitis\n\nFINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\n\nsummaries\n\nThe output should be formatted as a JSON instance that conforms to the JSON schema below.\n\nAs an example, for the schema {\"properties\": {\"foo\": {\"title\": \"Foo\", \"description\": \"a list of strings\", \"type\": \"array\", \"items\": {\"type\": \"string\"}}}, \"required\": [\"foo\"]}}\nthe object {\"foo\": [\"bar\", \"baz\"]} is a well-formatted instance of the schema. The object {\"properties\": {\"foo\": [\"bar\", \"baz\"]}} is not well-formatted.\n\nHere is the output schema:\n```\n{\"properties\": {\"drug_name\": {\"title\": \"Drug Name\", \"description\": \"Name of the drug\", \"type\": \"string\"}, \"advantages\": {\"title\": \"Advantages\", \"description\": \"Advantages of the drug \", \"type\": \"string\"}, \"disadvantages\": {\"title\": \"Disadvantages\", \"description\": \"Disadvantages of the drug\", \"type\": \"string\"}}, \"required\": [\"drug_name\", \"advantages\", \"disadvantages\"]}\n```\n\nQuestion: question\nAnswer:\n", "test_cases": [{"question": "40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations\n", "answer": "{\n  \"drug_name\": \"Infliximab (IFX)\",\n  \"advantages\": \"Best choice for patients with extraintestinal manifestations, such as articular involvement, and effective for newly diagnosed moderate UC.\",\n  \"disadvantages\": \"Potential side effects, including increased risk of infections and infusion reactions.\"\n},\n{\n  \"drug_name\": \"Golimumab (GOL)\",\n  \"advantages\": \"Second-best choice for patients with extraintestinal manifestations and effective for moderate UC.\",\n  \"disadvantages\": \"Less effective than Infliximab for extraintestinal manifestations and potential side effects, including increased risk of infections.\"\n}", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: Ustekinumab (USTE)\n5th Best: Vedoluzimab (VEDO)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis\nBest: Vedoluzimab (VEDO)\n2nd Best: Adalimumab (ADA)\n3rd Best: Infliximab (IFX)\n4th Best: Ustekinumab (USTE)\n5th Best: Golimumab (GOL)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)\nBest: Ustekinumab (USTE)\n2nd Best: Vedoluzimab (VEDO)\n3rd Best: \n4th Best: \n5th Best: "}]}, {"question": "70 year old female with newly diagnosed severe UC\n", "answer": "{\n  \"drug_name\": \"Ustekinumab (USTE)\",\n  \"advantages\": \"Best choice for patients aged over 65 with comorbidities due to its safety aspects data.\",\n  \"disadvantages\": \"Not the best choice for extraintestinal manifestations.\"\n},\n{\n  \"drug_name\": \"Vedolizumab (VEDO)\",\n  \"advantages\": \"Another top choice for patients aged over 65 with comorbidities due to its safety aspects data.\",\n  \"disadvantages\": \"Not the best choice for extraintestinal manifestations and may not be the best option during pregnancy.\"\n}", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL), Adalimumab (ADA)\n3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)\n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: Ustekinumab (USTE)\n5th Best: Vedoluzimab (VEDO)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)\nBest: Ustekinumab (USTE)\n2nd Best: Vedoluzimab (VEDO)\n3rd Best: \n4th Best: \n5th Best: "}]}, {"question": "35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance\n", "answer": "{\n  \"drug_name\": \"Ustekinumab (USTE)\",\n  \"advantages\": \"Effective in patients with prior failure to anti-TNF agents like Infliximab, lower risk of immunogenicity, and suitable for patients with extraintestinal manifestations.\",\n  \"disadvantages\": \"Less data available compared to other biologics, may have a slower onset of action, and requires subcutaneous injections.\"\n}", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: Ustekinumab (USTE)\n5th Best: Vedoluzimab (VEDO)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Vedolizumab\nBest: Infliximab (IFX)\n2nd Best: Ustekinumab (USTE), Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis\nBest: Vedoluzimab (VEDO)\n2nd Best: Adalimumab (ADA)\n3rd Best: Infliximab (IFX)\n4th Best: Ustekinumab (USTE)\n5th Best: Golimumab (GOL)"}]}, {"question": "60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure\n", "answer": "{\n  \"drug_name\": \"Ustekinumab (USTE)\",\n  \"advantages\": \"Best choice for patients with age > 65 and comorbidities, as it has a favorable safety profile.\",\n  \"disadvantages\": \"Not the best choice for pregnant patients, as it is ranked 3rd best in this category.\"\n},\n{\n  \"drug_name\": \"Vedolizumab (VEDO)\",\n  \"advantages\": \"2nd best choice for patients with age > 65 and comorbidities, and best choice for patients currently under maintenance.\",\n  \"disadvantages\": \"Not the best choice for pregnant patients, as it is ranked 3rd best in this category.\"\n}", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)\nBest: Ustekinumab (USTE)\n2nd Best: Vedoluzimab (VEDO)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL), Adalimumab (ADA)\n3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)\n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Currently under maintenance\nBest: Vedoluzimab (VEDO)\n2nd Best: Infliximab (IFX)\n3rd Best: Ustekinumab (USTE), Golimumab (GOL)\n4th Best: Adalimumab (ADA)\n5th Best: "}]}, {"question": "38 year old female with newly diagnosed moderate UC and psoriasis\n", "answer": "I don't know", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)\nBest: Ustekinumab (USTE)\n2nd Best: Vedoluzimab (VEDO)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL), Adalimumab (ADA)\n3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)\n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis\nBest: Vedoluzimab (VEDO)\n2nd Best: Adalimumab (ADA)\n3rd Best: Infliximab (IFX)\n4th Best: Ustekinumab (USTE)\n5th Best: Golimumab (GOL)"}]}, {"question": "25 year old pregnant woman with severe distal ulcerative colitis\n", "answer": "[\n  {\n    \"drug_name\": \"Infliximab (IFX)\",\n    \"advantages\": \"Best choice for pregnant patients with ulcerative colitis, effective in treating moderate to severe UC\",\n    \"disadvantages\": \"Potential side effects, risk of infusion reactions, and immunogenicity\"\n  },\n  {\n    \"drug_name\": \"Golimumab (GOL)\",\n    \"advantages\": \"Second best choice for pregnant patients with ulcerative colitis, effective in treating moderate to severe UC\",\n    \"disadvantages\": \"Less data available on safety and efficacy during pregnancy compared to Infliximab, potential side effects, and immunogenicity\"\n  }\n]", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL), Adalimumab (ADA)\n3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)\n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: Ustekinumab (USTE)\n5th Best: Vedoluzimab (VEDO)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis\nBest: Vedoluzimab (VEDO)\n2nd Best: Adalimumab (ADA)\n3rd Best: Infliximab (IFX)\n4th Best: Ustekinumab (USTE)\n5th Best: Golimumab (GOL)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}]}, {"question": "56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis\n", "answer": "{\n  \"drug_name\": \"Infliximab (IFX)\",\n  \"advantages\": \"Effective for both ulcerative colitis and extraintestinal manifestations such as ankylosing spondylitis\",\n  \"disadvantages\": \"Risk of infusion reactions and potential for immunogenicity\"\n},\n{\n  \"drug_name\": \"Adalimumab (ADA)\",\n  \"advantages\": \"Effective for both ulcerative colitis and extraintestinal manifestations such as ankylosing spondylitis; subcutaneous administration\",\n  \"disadvantages\": \"Potential for immunogenicity and injection site reactions\"\n}", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis\nBest: Vedoluzimab (VEDO)\n2nd Best: Adalimumab (ADA)\n3rd Best: Infliximab (IFX)\n4th Best: Ustekinumab (USTE)\n5th Best: Golimumab (GOL)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: Ustekinumab (USTE)\n5th Best: Vedoluzimab (VEDO)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Anti-TNF agents (1-2x) (PNR)\nBest: Ustekinumab (USTE)\n2nd Best: Vedoluzimab (VEDO)\n3rd Best: \n4th Best: \n5th Best: "}]}, {"question": "38 year old man with severe ulcerative colitis and has lost response to vedolizumab\n", "answer": "{\n  \"drug_name\": \"Infliximab (IFX)\",\n  \"advantages\": \"Best choice for patients with prior failure to Vedolizumab, effective in treating moderate to severe ulcerative colitis\",\n  \"disadvantages\": \"Risk of infusion reactions, potential for immunogenicity, and increased risk of infections\"\n},\n{\n  \"drug_name\": \"Ustekinumab (USTE)\",\n  \"advantages\": \"Second best choice for patients with prior failure to Vedolizumab, effective in treating moderate to severe ulcerative colitis\",\n  \"disadvantages\": \"Less data available compared to Infliximab, potential for immunogenicity, and increased risk of infections\"\n}", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis\nBest: Vedoluzimab (VEDO)\n2nd Best: Adalimumab (ADA)\n3rd Best: Infliximab (IFX)\n4th Best: Ustekinumab (USTE)\n5th Best: Golimumab (GOL)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Currently under maintenance\nBest: Vedoluzimab (VEDO)\n2nd Best: Infliximab (IFX)\n3rd Best: Ustekinumab (USTE), Golimumab (GOL)\n4th Best: Adalimumab (ADA)\n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Prior failure to Vedolizumab\nBest: Infliximab (IFX)\n2nd Best: Ustekinumab (USTE), Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: \n5th Best: "}]}, {"question": "28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago\n", "answer": "I don't know", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: Ustekinumab (USTE)\n5th Best: Vedoluzimab (VEDO)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis\nBest: Vedoluzimab (VEDO)\n2nd Best: Adalimumab (ADA)\n3rd Best: Infliximab (IFX)\n4th Best: Ustekinumab (USTE)\n5th Best: Golimumab (GOL)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL), Adalimumab (ADA)\n3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)\n4th Best: \n5th Best: "}]}, {"question": "36 year old woman with moderate ulcerative colitis and multiple sclerosis", "answer": "I don't know", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Age > 65 & comorbidities (safety aspects data)\nBest: Ustekinumab (USTE), Vedoluzimab (VEDO)\n2nd Best: Golimumab (GOL), Infliximab (IFX), Adalimumab (ADA)\n3rd Best: \n4th Best: \n5th Best: "}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Extraintestinale manifestation\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL)\n3rd Best: Adalimumab (ADA)\n4th Best: Ustekinumab (USTE)\n5th Best: Vedoluzimab (VEDO)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pouchitis\nBest: Vedoluzimab (VEDO)\n2nd Best: Adalimumab (ADA)\n3rd Best: Infliximab (IFX)\n4th Best: Ustekinumab (USTE)\n5th Best: Golimumab (GOL)"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3, "modal": "table", "text": "Efficacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics. :Patient Profile: Pregnancy\nBest: Infliximab (IFX)\n2nd Best: Golimumab (GOL), Adalimumab (ADA)\n3rd Best: Ustekinumab (USTE), Vedoluzimab (VEDO)\n4th Best: \n5th Best: "}]}]}